Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine.
AUTOR(ES)
Zimmerman, G A
RESUMO
Cerebral infarction (stroke) is a potentially disastrous complication of diabetes mellitus, principally because the extent of cortical loss is greater in diabetic patients than in nondiabetic patients. The etiology of this enhanced neurotoxicity is poorly understood. We hypothesized that advanced glycation endproducts (AGEs), which have previously been implicated in the development of other diabetic complications, might contribute to neurotoxicity and brain damage during ischemic stroke. Using a rat model of focal cerebral ischemia, we show that systemically administered AGE-modified bovine serum albumin (AGE-BSA) significantly increased cerebral infarct size. The neurotoxic effects of AGE-BSA administration were dose- and time-related and associated with a paradoxical increase in cerebral blood flow. Aminoguanidine, an inhibitor of AGE cross-linking, attenuated infarct volume in AGE-treated animals. We conclude that AGEs may contribute to the increased severity of stroke associated with diabetes and other conditions characterized by AGE accumulation.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=42038Documentos Relacionados
- Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine.
- Neuroprotective effects of gelsolin during murine stroke
- Advanced glycation endproducts in sepsis and mechanical ventilation: extra or leading man?
- Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene
- Relationship of advanced glycation end-products in hypertension in diabetic patients: a systematic review